BioLineRx (BLRX +0.5%) files to commence a Phase 1/2 trial in Finland for the celiac disease treatment BL-7010.
The study will evaluate the safety of single and repeated doses in well-controlled celiac patients.
Finland has a "significantly higher prevalence of celiac disease than other countries," CEO Kinneret Savitsky notes.
The study should commence in Q4. (PR)